Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rapid COJEC Versus Standard Induction Therapies for High‐risk Neuroblastoma." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433677/0/Desferrioxamine_mesylate_for_managing_transfusional_iron_overload_in_people_with_transfusion‐dependent_thalassaemia_Edited__no_change_to_conclusions_. Accessed 18 April 2024.
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433677/0/Desferrioxamine_mesylate_for_managing_transfusional_iron_overload_in_people_with_transfusion‐dependent_thalassaemia_Edited__no_change_to_conclusions_. Accessed April 18, 2024.
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/433677/0/Desferrioxamine_mesylate_for_managing_transfusional_iron_overload_in_people_with_transfusion‐dependent_thalassaemia_Edited__no_change_to_conclusions_
Rapid COJEC Versus Standard Induction Therapies for High‐risk Neuroblastoma [Internet]. In: Cochrane Abstracts. [cited 2024 April 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433677/0/Desferrioxamine_mesylate_for_managing_transfusional_iron_overload_in_people_with_transfusion‐dependent_thalassaemia_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
ID - 433677
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433677/0/Desferrioxamine_mesylate_for_managing_transfusional_iron_overload_in_people_with_transfusion‐dependent_thalassaemia_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -